The Human Vaccines Project, a nonprofit public-private partnership focused on decoding the immune system to improve human health, and Seqirus, a global leader in the prevention of influenza, announced that Seqirus is joining the Project’s Universal Influenza Vaccine Initiative (UIVI).
Seqirus (Melbourne, Australia), a vaccine company, has been on the front line of influenza vaccine development and pandemic preparedness for more than a century, pioneering new technologies for rapidly producing influenza vaccines.
Launched in late 2017, the UIVI is a collaboration of leading global organizations and partners working together to rapidly accelerate the development of a universal influenza vaccine that provides long-lasting protection against seasonal and pandemic influenza across demographics and geography. The Initiative fills a critical gap in influenza vaccine research today by focusing on how the immune system responds to and develops immunological protection against multiple strains of influenza. Research will be conducted using cutting-edge biomedical and machine learning technologies to develop models of the immune system. The models will be artificial intelligence-based, so they will get smarter over time, rapidly accelerating vaccine research.
Seqirus, headquartered in Melbourne, Australia is part of CSL Limited. The CSL Group of companies has operations in more than 60 countries. Seqirus was established in 2015 following CSL’s acquisition of the Novartis influenza vaccines business and its subsequent integration with bioCSL. Seqirus, one of the largest influenza vaccine providers, operates state-of-the-art production facilities in the U.S., the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies, as well as a proprietary adjuvant. It has leading R&D capabilities, a broad portfolio of differentiated products and a commercial presence in more than 20 countries.
Support and funders for the Human Vaccines Project include the Robert Wood Johnson Foundation, John D. and Catherine T. MacArthur Foundation, the Michelson Medical Research Foundation, GSK, MedImmune, Illumina, Johnson & Johnson/Janssen, Pfizer, Moderna, Boehringer Ingelheim, Aeras, Vanderbilt University Medical Center, Telethon Kids Institute, University of California San Diego, The Scripps Research Institute, J. Craig Venter Institute and La Jolla Institute for Allergy and Immunology.